

FORM PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. P29875	Application No. 10/577,343
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant Yasuharu NISHIMURA et al.	
		I.A. Filing Date October 28, 2004	Group 1643

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	2006	0 2 5 1 6 6 6	11/09/06	NAKATSURA et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	1	English language abstract of EP0561183 (corresponding to JP 6-46882 A, published February 22, 1994), provided by esp@cenet.
	2	English language abstract of WO 95/29193 (corresponding to JP 10-505481, published June 2, 1998) and provided by esp@cenet.
	3	U.S. Patent Application 12/063,165 (NISHIMURA et al.) filed February 7, 2008, and entitled "Glypican-3 (GPC-3)-Derived Tumor Rejection Antigenic Peptides Useful for HLA-A2-Positive Patients and Pharmaceutical Comprising the Same."
	4	U.S. Patent Application 12/155,864 (NAKATSURA et al.) filed June 11, 2008, and entitled "Cancer Antigen and Use Thereof."
	5	U.S. Patent Application 11/577,435 (NISHIMURA et al.), filed April 18, 2007, and entitled "Novel Diagnostic Kit for Malignant Melanoma."

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.